A Phase I/II trial shows AMT-130 gene therapy slowed Huntington's disease by 75% over three years, offering the strongest ...
6don MSN
Preliminary but promising gene therapy shows 75% reduction in Huntington's disease progression
A one-time experimental treatment shows unprecedented success in slowing Huntington's disease, according to UCL researchers.
Q2 2025 Earnings Call September 29, 2025 8:00 AM EDTCompany ParticipantsDai Kun - Founder, Chairman & CEOFeng Lin - ...
Form I-485, formally known as the “Application to Register Permanent Residence or Adjust Status,” is the official mechanism ...
Superintendent Brian Yearwood laid out "three key principles" that will guide the district's budget decisions.
Drugmaker uniQure reported the results of its small but “groundbreaking” Phase I/II study this week, finding that a high dose ...
Gaumont USA has also just wrapped production on Diego Luna-led ‘Mexico 86,’ as it taps its huge library for international ...
We tested popular battery-operated heated socks for men and women in the Lab and with consumer testers to find the best ones ...
A global clinical trial for a new Huntington’s disease treatment has posted positive results today, announced by trial ...
An experimental gene therapy has slowed the progression of Huntington’s disease by 75 percent, according to results reported ...
That is beginning to change. Across Europe and the United States, scientists are now testing AMT‑130, an experimental gene therapy from the biotech firm uniQure. It is the first therapy designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback